$Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia$

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia

Bibliografski detalji
Glavni autori:	Amarnani, R, Travis, S, Javaid, MK
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2020

Slični predmeti

Treating ‘osteoporosis’: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia
od: Mike Lin, i dr.
Izdano: (2022-11-01)

A Rare Case of Hypophosphataemic Osteomalacia in von Recklinghausen Neurofibromatosis
od: Yasmine Makhlouf, i dr.
Izdano: (2021-05-01)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
od: L Aliberti, i dr.
Izdano: (2023-01-01)

Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia
od: Magda Wojtuś, i dr.
Izdano: (2023-07-01)

Selective blood sampling for FGF-23 in tumor-induced osteomalacia
od: Hans-Christof Schober, i dr.
Izdano: (2017-10-01)

Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature
od: Ramy H. Bishay, i dr.
Izdano: (2017-01-01)

Hypophosphatemic osteomalacia induced by FGF23-secreting tumor of the left femur
od: S. S. Rodionova, i dr.
Izdano: (2019-12-01)

A Normal FGF23 Does Not Preclude Tumor‐Induced Osteomalacia
od: Neeharika Nandam, i dr.
Izdano: (2021-02-01)

Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia
od: Seiji Fukumoto
Izdano: (2014-06-01)

An image of a FGF-23-producing tumor resulting in osteomalacia
od: Marcelo Giacomini Louça, i dr.
Izdano: (2024-06-01)

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption
od: Naoko Hidaka, i dr.
Izdano: (2021-12-01)

Phosphopenic form of osteomalacia in a patient with FGF23 producing tumor
od: A. S. Pushkareva, i dr.
Izdano: (2022-05-01)

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
od: Iris R. Hartley, i dr.
Izdano: (2022-08-01)

Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
od: Hannan, F, i dr.
Izdano: (2008)

De Novo Large Deletions in the <i>PHEX</i> Gene Caused X-Linked Hypophosphataemic Rickets in Two Italian Female Infants Successfully Treated with Burosumab
od: Carmine Pecoraro, i dr.
Izdano: (2023-07-01)

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)
od: Yuka Kinoshita, i dr.
Izdano: (2019-06-01)

A Case of Acute Prosthesis Migration after Femoral Head Replacement due to Osteomalacia by FGF23-Induced Tumor
od: Shinya Hayashi, i dr.
Izdano: (2012-01-01)

Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin
od: Anke H. Hautmann, i dr.
Izdano: (2014-01-01)

Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome
od: S. Kumar, i dr.
Izdano: (2020-06-01)

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report
od: Daichi Miyaoka, i dr.
Izdano: (2020-12-01)

FGF-23 transmitted tumor – induced hypophosphatemic osteomalacia: A rare case of a young woman with recurrent fractures and review of the literature
od: Florian A. Frank, i dr.
Izdano: (2022-04-01)

A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
od: Carson Huynh, i dr.
Izdano: (2022-12-01)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
od: Yuichi Takashi, i dr.
Izdano: (2022-12-01)

Predicting the impact of PHEX, FGF23 and DMP1 gene variants found in Malaysian Malay patients with Hypophosphataemic Rickets through in silico analysis of protein function and mRNA secondary structure
od: Razali, Nurul Nadirah, i dr.
Izdano: (2019)

Windswept lower limb deformities in patients with hypophosphataemic rickets
od: Ali Al Kaissi, i dr.
Izdano: (2013-12-01)

A case report of mesenchymal scapular FGF secreting tumor: Importance of follow up in tumor induced osteomalacia
od: Trilok Shrivastava, MD, i dr.
Izdano: (2021-04-01)

Tumor-induced osteomalacia
od: Zinan Yin, i dr.
Izdano: (2018-12-01)

Tumor-induced osteomalacia
od: Pablo Florenzano, i dr.
Izdano: (2017-12-01)

The role of narrowband ultraviolet B phototherapy in the treatment of refractory osteomalacia
od: João Teixeira, i dr.
Izdano: (2024-10-01)

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial
od: Peter Kamenický, i dr.
Izdano: (2020-10-01)

Phosphorus-independent role of FGF23 in erythropoiesis and iron homeostasis.
od: Min Young Park, i dr.
Izdano: (2024-01-01)

Seven novel mutations in the PEX gene indicate molecular heterogeneity for X-linked hypophosphataemic rickets.
od: Dixon, P, i dr.
Izdano: (1996)

Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
od: Lillian Abebe, i dr.
Izdano: (2024-03-01)

Mapping of human X-linked hypophosphataemic rickets by multilocus linkage analysis.
od: Read, A, i dr.
Izdano: (1986)

X-linked hypophosphataemic rickets due to pseudo-exons of the PHEX gene.
od: Christie, P, i dr.
Izdano: (2000)

Bridging markers defining the map position of X linked hypophosphataemic rickets.
od: Thakker, R, i dr.
Izdano: (1987)

Genetic basis of hereditary hypophosphataemic rickets and phenotype presentation in children and adults
od: Tavana, Nahid, i dr.
Izdano: (2021)

Osteomalacia
od: Ricardo Cediel
Izdano: (1958-09-01)

Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
od: Ai-Luen Wu, i dr.
Izdano: (2013-01-01)

Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
od: Kanhasut, Karnpob, i dr.
Izdano: (2023)